Publicerad 22 Feb 2012 av
BolagsFakta
ABLYNX ANNOUNCES 2011 FULL YEAR RESULTS
Strong year of progress at Ablynx as first Nanobody® reaches clinical proof-of-concept GHENT, Belgium, 22nd February 2012 - Ablynx (Euronext Brussels: ABLX), the Belgian-based biopharmaceutical company focused on the discovery and development of Nanobodies for the treatment...
Dela med andra